Cas no 13182-89-3 (Metronidazole benzoate)
Metronidazole benzoate Chemical and Physical Properties
Names and Identifiers
-
- 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate
- Benzoylmetronildazole
- Benzoyl metronidazole
- METRONIDAZOLE BENZOATE
- benzoylmetronidazolebenzoylmetronildazole
- 2-Methyl-5-nitro-1H-imidazole-1-ethyl benzoate
- Metronidazole Impurity 8
- METRONIDAZOLEBENZOATE,POWDER
- METRONIDAZOLE BENZOATE(BP2002)
- Metronidazole Benzoate (100 mg)
- METRONIDAZOLEBENZOATE,POWDER,BP
- MetronidazoleBenzoateMetronidazoleBenzoateBp
- benzoylmetronidazole
- 2-(2-methyl-5-nitro-imidazol-1-yl)ethyl benzoate
- AC-33577
- METRONIDAZOLE BENZOATE (EP MONOGRAPH)
- AC-14443
- METRONIDAZOLE BENZOATE (USP-RS)
- NS00020740
- AKOS040733724
- 1H-Imidazole-1-ethanol, 2-methyl-5-nitro-, 1-benzoate
- Metronidazole Benzoate;Benzoyl metronidazole
- Oprea1_489419
- Klion suspension
- MFCD00693654
- METRONIDAZOLE BENZOATE [WHO-IP]
- CHEBI:50688
- METRONIDAZOLE BENZOATE [USP MONOGRAPH]
- benzoic acid 2-(2-methyl-5-nitro-1-imidazolyl)ethyl ester
- AKOS015888108
- Flagyl S
- Metronidazoli benzoas
- SolutitionKitsMetronidazole
- METRONIDAZOLE BENZOATE [MART.]
- Benzoic acid 2-(2-methyl-5-nitro-imidazol-1-yl)-ethyl ester
- DTXSID60157221
- SMR000217345
- EINECS 236-131-7
- BCP28722
- Metronidazole benzoate (USP)
- DTXCID0079712
- AS-13537
- METRONIDAZOLI BENZOAS [WHO-IP LATIN]
- 2-(2-methyl-5-nitroimidazol-1-yl)ethyl benzoate
- C90395
- Metronidazole benzoate; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate
- s5863
- A355C835XC
- Metronidazole benzoate (USP:BAN)
- METRONIDAZOLE BENZOATE [USP-RS]
- NCGC00160502-01
- A806316
- CCG-253836
- 13182-89-3
- 5-nitro-2-methyl-1-(2-benzoyloxyethyl)-imidazole
- Benzoylmetronildazole;
- HY-122975
- AB06961
- METRONIDAZOLE BENZOATE [WHO-DD]
- Metronidazole benzoate [USP:BAN]
- METRONIDAZOLE BENZOATE (USP MONOGRAPH)
- SCHEMBL366213
- Q12199321
- UNII-A355C835XC
- MLS000590415
- CS-0090787
- METRONIDAZOLE BENZOATE (MART.)
- METRONIDAZOLE BENZOATE [EP MONOGRAPH]
- CHEMBL1466172
- D08214
- HMS2569A06
- FT-0628935
- Elyzol (TN)
- DB-042064
- Metronidazole benzoate
-
- MDL： MFCD00693654
- Inchi： 1S/C13H13N3O4/c1-10-14-9-12(16(18)19)15(10)7-8-20-13(17)11-5-3-2-4-6-11/h2-6,9H,7-8H2,1H3
- InChI Key： CUUCCLJJOWSASK-UHFFFAOYSA-N
- SMILES： O(C(C1C=CC=CC=1)=O)CCN1C(=CN=C1C)[N+](=O)[O-]
Computed Properties
- Exact Mass: 275.09100
- Monoisotopic Mass: 275.091
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 20
- Rotatable Bond Count: 6
- Complexity: 352
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: nothing
- XLogP3: nothing
- Topological Polar Surface Area: 89.9A^2
Experimental Properties
- Color/Form: No data avaiable
- Density: 1.31
- Melting Point: 99-103°C
- Boiling Point: 579.4°C at 760 mmHg
- Flash Point: 248.7°C
- PSA: 89.94000
- LogP: 2.47990
- Vapor Pressure: No data available
Metronidazole benzoate Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
- Hazardous Material transportation number：NONH for all modes of transport
- Safety Instruction： H302 (42.86%) H312 (28.57%) H315 (14.29%)
- Storage Condition：2-8°C
Metronidazole benzoate Customs Data
- HS CODE：2933990090
- Customs Data：
China Customs Code:
2933290090Overview:
2933290090. Other compounds with non fused imidazole ring in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Metronidazole benzoate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | BP735 |
Metronidazole benzoate |
13182-89-3 | 100mg |
￥1897.11 | 2023-04-25 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | M1851000 |
Metronidazole benzoate |
13182-89-3 | European Pharmacopoeia (EP) Reference Standard | ￥2654.27 | 2022-02-23 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 1442100-100MG |
Metronidazole benzoate |
13182-89-3 | 100mg |
￥3302.56 | 2024-12-23 | ||
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | B856833-2.5kg |
Benzoylmetronildazole |
13182-89-3 | 99%,BP | 2.5kg |
2,769.00 | 2021-05-17 | |
| Fluorochem | 212642-1g |
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylbenzoate |
13182-89-3 | 95% | 1g |
￡13.00 | 2022-03-01 | |
| Fluorochem | 212642-5g |
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylbenzoate |
13182-89-3 | 95% | 5g |
￡39.00 | 2022-03-01 | |
| Fluorochem | 212642-10g |
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylbenzoate |
13182-89-3 | 95% | 10g |
￡65.00 | 2022-03-01 | |
| Fluorochem | 212642-25g |
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylbenzoate |
13182-89-3 | 95% | 25g |
￡128.00 | 2022-03-01 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-HH571-20g |
Metronidazole benzoate |
13182-89-3 | 98% | 20g |
59.0CNY | 2021-08-04 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-HH571-100g |
Metronidazole benzoate |
13182-89-3 | 98% | 100g |
213.0CNY | 2021-08-04 |
Metronidazole benzoate Suppliers
Audited Supplier
Metronidazole benzoate Related Literature
-
Wendell Saraiva Costa,Yara Santiago de Oliveira,Alejandro Pedro Ayala CrystEngComm 2023 25 4716
-
Yu-Qin Niu,Jia-Hui Liu,Cyril Aymonier,Simona Fermani,Damir Kralj,Giuseppe Falini,Chun-Hui Zhou Chem. Soc. Rev. 2022 51 7883
-
Samar A. Salim,Noha M. Badawi,Shahira H. EL-Moslamy,Elbadawy A. Kamoun,Baher A. Daihom RSC Adv. 2023 13 14943
Additional information on Metronidazole benzoate
Introduction to Metronidazole Benzoate (CAS No. 13182-89-3)
Metronidazole benzoate, a derivative of the well-known antibiotic Metronidazole, is a compound of significant interest in the field of pharmaceutical chemistry and biomedicine. With the CAS number CAS No. 13182-89-3, this substance has garnered attention for its potential applications in treating various infections and its unique chemical properties. This article delves into the compound's structure, mechanisms of action, recent research findings, and future prospects.
The chemical structure of Metronidazole benzoate consists of a nitroimidazole core linked to a benzoate moiety. This modification enhances the solubility and stability of the compound, making it more suitable for pharmaceutical formulations. The nitroimidazole group is known for its antimicrobial properties, particularly against anaerobic bacteria and certain protozoa. The benzoate component contributes to the overall pharmacokinetic profile, improving bioavailability and reducing potential side effects.
In recent years, research on Metronidazole benzoate has expanded beyond its traditional applications. Studies have explored its efficacy in treating resistant bacterial infections and its potential as a therapeutic agent in chronic inflammatory conditions. One notable area of research is its role in combating multidrug-resistant bacteria, where Metronidazole benzoate has shown promise in preclinical trials. The ability of this compound to disrupt bacterial DNA synthesis and metabolic pathways makes it a valuable asset in the fight against antibiotic-resistant strains.
Furthermore, the compound has been investigated for its anti-inflammatory properties. Emerging evidence suggests that Metronidazole benzoate can modulate inflammatory responses by inhibiting key enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). These enzymes are crucial in the production of pro-inflammatory cytokines, making Metronidazole benzoate a potential candidate for treating conditions like rheumatoid arthritis and inflammatory bowel disease. Clinical trials are currently underway to evaluate its efficacy and safety in these applications.
The pharmacokinetic profile of Metronidazole benzoate is another area of active investigation. Unlike its parent compound, Metronidazole, which has a relatively short half-life, the benzoate derivative exhibits improved oral bioavailability and prolonged half-life. This makes it more convenient for patients requiring long-term treatment regimens. Additionally, studies have shown that Metronidazole benzoate undergoes metabolic conversion to active metabolites, ensuring sustained therapeutic effects.
Recent advances in drug delivery systems have also highlighted the potential of Metronidazole benzoate. Nanoparticle formulations and liposomes have been explored as vehicles for delivering this compound, enhancing its targeted action and reducing systemic side effects. These innovations are particularly promising for treating localized infections and improving patient compliance.
The safety profile of Metronidazole benzoate is another critical aspect that has been thoroughly evaluated. While it shares some common side effects with its parent compound, such as gastrointestinal discomfort and metallic taste, studies suggest that these can be mitigated through dosage adjustments and combination therapies. Long-term studies are ongoing to assess the compound's impact on liver function and other organ systems.
In conclusion, Metronidazole benzoate represents a significant advancement in antimicrobial therapy with broad applications in both infectious diseases and inflammatory conditions. Its enhanced solubility, improved pharmacokinetics, and novel mechanisms of action make it a promising candidate for future clinical use. As research continues to uncover new therapeutic possibilities, Metronidazole benzoate is poised to play a vital role in addressing global health challenges related to infections and inflammation.
13182-89-3 (Metronidazole benzoate) Related Products
- 87009-72-1(Benzoic acid 2-(2-methyl-4-nitro-1-imidazolyl)ethyl ester)
- 103470-83-3(Benzeneacetic acid,2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester)
- 119295-34-0(1H-Imidazole-1-ethanol, 2-mehyl-5-nitro-2-(2,4-dichlorophenoxy)phenol)
- 104575-34-0(Benzoic acid,3,4,5-tris(acetyloxy)-, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester)
- 1016-40-6(1H-Imidazole-1-aceticacid, 2-methyl-5-nitro-, ethyl ester)
- 13182-82-6(Metronidazole Acetate)
- 89218-56-4(Glycine, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester)
- 89218-55-3(Glycine, N,N-dimethyl-, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester)
- 104575-36-2(Benzoic acid,3,4,5-trimethoxy-, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester)
- 298688-51-4(2-(Bis(2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-2-oxoethyl)amino)acetic acid)
